CV0701 / CureVac, GSK - LARVOL DELTA

Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial. (PubMed, Hum Vaccin Immunother) - P2 | "The CV0701 and CV0601 mRNA vaccines elicited robust humoral and cellular immunity with an acceptable safety profile, comparable to a licensed, bivalent mRNA vaccine. Clinical Trial Registration EU CT number: 2023-504596-25-00 ClinicalTrials.gov: NCT05960097."

Clinical • Journal • P2 data • Cardiovascular • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults (clinicaltrials.gov) - P2 | N=675 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults (clinicaltrials.gov) - P2 | N=664 | Active, not recruiting | Sponsor: GlaxoSmithKline | N=427 ➔ 664

Enrollment change • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults (clinicaltrials.gov) - P2 | N=427 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2024 ➔ Sep 2024 | Trial primary completion date: Mar 2024 ➔ Sep 2024

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults (clinicaltrials.gov) - P2 | N=415 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study on the Safety and Immune Response of a Booster Dose of Investigational COVID-19 mRNA Vaccines in Healthy Adults (clinicaltrials.gov) - P2 | N=415 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases